TrialNeuro-oncology2007

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Karla V Ballman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.